Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/26500
Title: | GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and meta-analysis protocol |
Authors: | Chawar C Hillmer A Sanger S D’Elia A Panesar B Guan L Xie DX Bansal N Abdullah A Kapczinski F Pare G Thabane L Samaan Z |
Keywords: | Genome-wide association;Medication-assisted treatment;Opioid use;Pharmacogenetics;Protocol;SNP;Systematic review;Treatment response |
Publication Date: | Dec-2020 |
Publisher: | Springer Science and Business Media LLC |
Abstract: | BACKGROUND: The burden of opioid use disorder (OUD) has been increasing in North America. Administration of medication-assisted treatments (MATs) for OUD on an individual-dose basis has been shown to affect patient responses to treatment, proving to be, on occasion, dangerous. A genetic basis has been identified for some MAT responses in a candidate gene context, but consensus has not been reached for any genome-wide significant associations. This systematic review aims to identify and assess any genetic variants associated with MAT patient outcomes at genome-wide significance. METHODS: The databases searched by the authors will be: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog, GWAS Central, and NIH Database of Genotypes and Phenotypes. A title and abstract screening, full-text screening, data extraction, and quality assessment will be completed in duplicate for each study via Covidence. Treatment outcomes of interest include continued opioid use or abstinence during treatment or at follow-up, time to relapse, treatment retention rates, opioid overdose, other substance use, comorbid psychiatric disorders, risk taking behaviors, MAT plasma concentrations, and mortality rates. Analysis methods applied, if appropriate, will include random effects meta-analysis with pooled odds ratios for all outcomes. Subgroup analyses will also be implemented, when possible. DISCUSSION: This systematic review can hopefully inform the direction of future research, aiding in the development of a safer and more patient-centered treatment. It will be able to highlight genome-wide significant variants that are replicable and associated with MAT patient outcomes. SYSTEMATIC REVIEW REGISTRATION: This systematic review protocol has been registered with the International Prospective Register of Systematic Reviews (PROSPERO) (registration ID CRD42020169121). |
metadata.dc.rights.license: | Attribution - CC BY |
Rights: | Attribution - CC BY This Creative Commons license lets others distribute, remix, tweak, and build upon your work, even commercially, as long as they credit you for the original creation. Recommended for maximum dissemination and use of licensed materials. |
URI: | http://hdl.handle.net/11375/26500 |
metadata.dc.identifier.doi: | https://doi.org/10.1186/s13643-020-01461-z |
ISSN: | 2046-4053 2046-4053 |
Appears in Collections: | Faculty Publications (via McMaster Experts) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder.pdf | Published version | 321.79 kB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.